Back to top

gene-editing: Archive

Zacks Equity Research

CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates

CRISPR Therapeutics posts a wider Q4 loss and revenues miss, but Casgevy sales climb, with label expansion plans and pipeline updates ahead.

ALKSNegative Net Change VRTXPositive Net Change CRSPPositive Net Change CSTLPositive Net Change